ID   TRIO_HUMAN              Reviewed;        3097 AA.
AC   O75962; D3DTD1; Q13458; Q59EQ7; Q6PJC9; Q6ZN05; Q8IWK8;
DT   01-DEC-2000, integrated into UniProtKB/Swiss-Prot.
DT   01-SEP-2009, sequence version 2.
DT   10-MAY-2017, entry version 181.
DE   RecName: Full=Triple functional domain protein;
DE            EC=2.7.11.1;
DE   AltName: Full=PTPRF-interacting protein;
GN   Name=TRIO;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15372022; DOI=10.1038/nature02919;
RA   Schmutz J., Martin J., Terry A., Couronne O., Grimwood J., Lowry S.,
RA   Gordon L.A., Scott D., Xie G., Huang W., Hellsten U., Tran-Gyamfi M.,
RA   She X., Prabhakar S., Aerts A., Altherr M., Bajorek E., Black S.,
RA   Branscomb E., Caoile C., Challacombe J.F., Chan Y.M., Denys M.,
RA   Detter J.C., Escobar J., Flowers D., Fotopulos D., Glavina T.,
RA   Gomez M., Gonzales E., Goodstein D., Grigoriev I., Groza M.,
RA   Hammon N., Hawkins T., Haydu L., Israni S., Jett J., Kadner K.,
RA   Kimball H., Kobayashi A., Lopez F., Lou Y., Martinez D., Medina C.,
RA   Morgan J., Nandkeshwar R., Noonan J.P., Pitluck S., Pollard M.,
RA   Predki P., Priest J., Ramirez L., Retterer J., Rodriguez A.,
RA   Rogers S., Salamov A., Salazar A., Thayer N., Tice H., Tsai M.,
RA   Ustaszewska A., Vo N., Wheeler J., Wu K., Yang J., Dickson M.,
RA   Cheng J.-F., Eichler E.E., Olsen A., Pennacchio L.A., Rokhsar D.S.,
RA   Richardson P., Lucas S.M., Myers R.M., Rubin E.M.;
RT   "The DNA sequence and comparative analysis of human chromosome 5.";
RL   Nature 431:268-274(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1-1686 (ISOFORM 4), AND
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2715-3097 (ISOFORM 1).
RC   TISSUE=Kidney, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-3097 (ISOFORM 2), FUNCTION,
RP   INTERACTION WITH PTPRF, AND TISSUE SPECIFICITY.
RC   TISSUE=Fibroblast;
RX   PubMed=8643598; DOI=10.1073/pnas.93.11.5466;
RA   Debant A., Serra-Pages C., Seipel K., O'Brien S., Tang M., Park S.-H.,
RA   Streuli M.;
RT   "The multidomain protein Trio binds the LAR transmembrane tyrosine
RT   phosphatase, contains a protein kinase domain, and has separate rac-
RT   specific and rho-specific guanine nucleotide exchange factor
RT   domains.";
RL   Proc. Natl. Acad. Sci. U.S.A. 93:5466-5471(1996).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 38-3097 (ISOFORM 1).
RA   Streuli M.;
RL   Submitted (SEP-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 362-3097 (ISOFORM 5).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   FUNCTION.
RX   PubMed=10341202;
RA   Seipel K., Medley Q.G., Kedersha N.L., Zhang X.A., O'Brien S.P.,
RA   Serra-Pages C., Hemler M.E., Streuli M.;
RT   "Trio amino-terminal guanine nucleotide exchange factor domain
RT   expression promotes actin cytoskeleton reorganization, cell migration
RT   and anchorage-independent cell growth.";
RL   J. Cell Sci. 112:1825-1834(1999).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2282 AND SER-2455, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   INTERACTION WITH CARMIL1.
RX   PubMed=19846667; DOI=10.1091/mbc.E08-10-1071;
RA   Liang Y., Niederstrasser H., Edwards M., Jackson C.E., Cooper J.A.;
RT   "Distinct roles for CARMIL isoforms in cell migration.";
RL   Mol. Biol. Cell 20:5290-5305(2009).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2455 AND SER-2459, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2455; SER-2459 AND
RP   SER-2631, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   INVOLVEMENT IN MRD44, AND VARIANTS MRD44 SER-924; HIS-1238; THR-1922;
RP   ASN-1939; VAL-2201; ASP-2247 AND GLN-2707.
RX   PubMed=26721934; DOI=10.1093/hmg/ddv618;
RA   Ba W., Yan Y., Reijnders M.R., Schuurs-Hoeijmakers J.H., Feenstra I.,
RA   Bongers E.M., Bosch D.G., De Leeuw N., Pfundt R., Gilissen C.,
RA   De Vries P.F., Veltman J.A., Hoischen A., Mefford H.C., Eichler E.E.,
RA   Vissers L.E., Nadif Kasri N., De Vries B.B.;
RT   "TRIO loss of function is associated with mild intellectual disability
RT   and affects dendritic branching and synapse function.";
RL   Hum. Mol. Genet. 25:892-902(2016).
RN   [18]
RP   INVOLVEMENT IN MRD44, VARIANTS MRD44 ILE-1080; GLN-1428 AND THR-1461,
RP   CHARACTERIZATION OF VARIANTS MRD44 ILE-1080; GLN-1428 AND THR-1461,
RP   AND FUNCTION.
RX   PubMed=27418539; DOI=10.1136/jmedgenet-2016-103942;
RA   Pengelly R.J., Greville-Heygate S., Schmidt S., Seaby E.G.,
RA   Jabalameli M.R., Mehta S.G., Parker M.J., Goudie D.,
RA   Fagotto-Kaufmann C., Mercer C., Debant A., Ennis S., Baralle D.;
RT   "Mutations specific to the Rac-GEF domain of TRIO cause intellectual
RT   disability and microcephaly.";
RL   J. Med. Genet. 0:0-0(2016).
RN   [19]
RP   STRUCTURE BY NMR OF 1286-1466, AND MUTAGENESIS.
RX   PubMed=9790533; DOI=10.1016/S0092-8674(00)81757-2;
RA   Liu X., Wang H., Eberstadt M., Schnuchel A., Olejniczak E.T.,
RA   Meadows R.P., Schkeryantz J.M., Janowick D.A., Harlan J.E.,
RA   Harris E.A.S., Staunton D.E., Fesik S.W.;
RT   "NMR structure and mutagenesis of the N-terminal Dbl homology domain
RT   of the nucleotide exchange factor Trio.";
RL   Cell 95:269-277(1998).
RN   [20]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-291; MET-1644; ARG-1690; MET-1978
RP   AND MET-2242.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [21]
RP   VARIANTS VAL-1368 AND MET-2563.
RX   PubMed=23033978; DOI=10.1056/NEJMoa1206524;
RA   de Ligt J., Willemsen M.H., van Bon B.W., Kleefstra T., Yntema H.G.,
RA   Kroes T., Vulto-van Silfhout A.T., Koolen D.A., de Vries P.,
RA   Gilissen C., del Rosario M., Hoischen A., Scheffer H., de Vries B.B.,
RA   Brunner H.G., Veltman J.A., Vissers L.E.;
RT   "Diagnostic exome sequencing in persons with severe intellectual
RT   disability.";
RL   N. Engl. J. Med. 367:1921-1929(2012).
CC   -!- FUNCTION: Guanine nucleotide exchange factor (GEF) for RHOA and
CC       RAC1 GTPases (PubMed:8643598, PubMed:27418539). Involved in
CC       coordinating actin remodeling, which is necessary for cell
CC       migration and growth (PubMed:10341202). In developing hippocampal
CC       neurons, limits dendrite formation, without affecting the
CC       establishment of axon polarity. Once dendrites are formed,
CC       involved in the control of synaptic function by regulating the
CC       endocytosis of AMPA-selective glutamate receptors (AMPARs) at CA1
CC       excitatory synapses (By similarity).
CC       {ECO:0000250|UniProtKB:F1M0Z1, ECO:0000269|PubMed:10341202,
CC       ECO:0000269|PubMed:27418539, ECO:0000269|PubMed:8643598}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts with CARMIL1 (PubMed:19846667). Interacts with
CC       PTPRF/LAR (PubMed:8643598). {ECO:0000269|PubMed:19846667,
CC       ECO:0000269|PubMed:8643598}.
CC   -!- INTERACTION:
CC       Q9NRI5:DISC1; NbExp=3; IntAct=EBI-718519, EBI-529989;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:Q0KL02}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=O75962-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O75962-2; Sequence=VSP_004467, VSP_004468;
CC         Note=Ref.5 (AAC34245) sequence differs from that shown due to a
CC         frameshift in position 2301. {ECO:0000305};
CC       Name=3;
CC         IsoId=O75962-3; Sequence=VSP_023306, VSP_023307;
CC         Note=No experimental confirmation available.;
CC       Name=4;
CC         IsoId=O75962-4; Sequence=VSP_037860;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=O75962-5; Sequence=VSP_037861, VSP_037862;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Widely expressed, with highest levels in
CC       heart, skeletal muscle, and brain. {ECO:0000269|PubMed:8643598}.
CC   -!- DOMAIN: The N-terminal DBL/GEF domain specifically catalyzes
CC       nucleotide exchange for RAC1, leading to the activation of Jun
CC       kinase and the production of membrane ruffles. The second DBL/GEF
CC       domain is an exchange factor for rhoa and induces the formation of
CC       stress fibers.
CC   -!- PTM: Phosphorylated on serine residue(s).
CC   -!- DISEASE: Mental retardation, autosomal dominant 44 (MRD44)
CC       [MIM:617061]: A form of mental retardation, a disorder
CC       characterized by significantly below average general intellectual
CC       functioning associated with impairments in adaptive behavior and
CC       manifested during the developmental period. MRD44 patients
CC       manifest developmental delay, variable intellectual disability,
CC       distinctive facial features, and abnormalities of the fingers.
CC       Most patients also have microcephaly.
CC       {ECO:0000269|PubMed:26721934, ECO:0000269|PubMed:27418539}.
CC       Note=The disease may be caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAC34245.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC       Sequence=AAC34245.1; Type=Frameshift; Positions=2301; Evidence={ECO:0000305};
CC       Sequence=AAC43042.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TRIOID43542ch5p15.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AK131423; BAD18570.1; -; mRNA.
DR   EMBL; AC010419; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016549; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016654; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC016656; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC026456; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471102; EAX08047.1; -; Genomic_DNA.
DR   EMBL; CH471102; EAX08048.1; -; Genomic_DNA.
DR   EMBL; BC035585; AAH35585.1; -; mRNA.
DR   EMBL; BC017268; AAH17268.1; -; mRNA.
DR   EMBL; U42390; AAC34245.1; ALT_SEQ; mRNA.
DR   EMBL; AF091395; AAC43042.1; ALT_INIT; mRNA.
DR   EMBL; AB209754; BAD92991.1; -; mRNA.
DR   CCDS; CCDS3883.1; -. [O75962-1]
DR   RefSeq; NP_009049.2; NM_007118.3. [O75962-1]
DR   RefSeq; XP_011512412.1; XM_011514110.2. [O75962-4]
DR   UniGene; Hs.130031; -.
DR   PDB; 1NTY; X-ray; 1.70 A; A=1284-1594.
DR   PDB; 2NZ8; X-ray; 2.00 A; B=1285-1594.
DR   PDBsum; 1NTY; -.
DR   PDBsum; 2NZ8; -.
DR   ProteinModelPortal; O75962; -.
DR   SMR; O75962; -.
DR   BioGrid; 113055; 28.
DR   DIP; DIP-37578N; -.
DR   IntAct; O75962; 12.
DR   MINT; MINT-1397752; -.
DR   STRING; 9606.ENSP00000339299; -.
DR   iPTMnet; O75962; -.
DR   PhosphoSitePlus; O75962; -.
DR   BioMuta; TRIO; -.
DR   EPD; O75962; -.
DR   MaxQB; O75962; -.
DR   PaxDb; O75962; -.
DR   PeptideAtlas; O75962; -.
DR   PRIDE; O75962; -.
DR   Ensembl; ENST00000344135; ENSP00000339291; ENSG00000038382. [O75962-3]
DR   Ensembl; ENST00000344204; ENSP00000339299; ENSG00000038382. [O75962-1]
DR   GeneID; 7204; -.
DR   KEGG; hsa:7204; -.
DR   UCSC; uc003jff.4; human. [O75962-1]
DR   CTD; 7204; -.
DR   DisGeNET; 7204; -.
DR   GeneCards; TRIO; -.
DR   HGNC; HGNC:12303; TRIO.
DR   HPA; HPA008157; -.
DR   HPA; HPA064664; -.
DR   MIM; 601893; gene.
DR   MIM; 617061; phenotype.
DR   neXtProt; NX_O75962; -.
DR   OpenTargets; ENSG00000038382; -.
DR   PharmGKB; PA36982; -.
DR   eggNOG; KOG0032; Eukaryota.
DR   eggNOG; KOG4240; Eukaryota.
DR   eggNOG; ENOG410XPCA; LUCA.
DR   GeneTree; ENSGT00760000119030; -.
DR   HOGENOM; HOG000044462; -.
DR   HOVERGEN; HBG108598; -.
DR   InParanoid; O75962; -.
DR   KO; K08810; -.
DR   OMA; AEPIPKM; -.
DR   OrthoDB; EOG091G00JY; -.
DR   PhylomeDB; O75962; -.
DR   TreeFam; TF318080; -.
DR   Reactome; R-HSA-193648; NRAGE signals death through JNK.
DR   Reactome; R-HSA-194840; Rho GTPase cycle.
DR   Reactome; R-HSA-416476; G alpha (q) signalling events.
DR   Reactome; R-HSA-416482; G alpha (12/13) signalling events.
DR   Reactome; R-HSA-418885; DCC mediated attractive signaling.
DR   SignaLink; O75962; -.
DR   SIGNOR; O75962; -.
DR   ChiTaRS; TRIO; human.
DR   EvolutionaryTrace; O75962; -.
DR   GeneWiki; TRIO_(gene); -.
DR   GenomeRNAi; 7204; -.
DR   PRO; PR:O75962; -.
DR   Proteomes; UP000005640; Chromosome 5.
DR   Bgee; ENSG00000038382; -.
DR   CleanEx; HS_TRIO; -.
DR   ExpressionAtlas; O75962; baseline and differential.
DR   Genevisible; O75962; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0019899; F:enzyme binding; IEA:Ensembl.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:ProtInc.
DR   GO; GO:0005089; F:Rho guanyl-nucleotide exchange factor activity; TAS:Reactome.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; TAS:Reactome.
DR   GO; GO:0035023; P:regulation of Rho protein signal transduction; IEA:InterPro.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007185; P:transmembrane receptor protein tyrosine phosphatase signaling pathway; TAS:ProtInc.
DR   CDD; cd00170; SEC14; 1.
DR   Gene3D; 2.30.29.30; -; 2.
DR   Gene3D; 2.60.40.10; -; 1.
DR   Gene3D; 3.40.525.10; -; 1.
DR   InterPro; IPR001251; CRAL-TRIO_dom.
DR   InterPro; IPR000219; DH-domain.
DR   InterPro; IPR007110; Ig-like_dom.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR013098; Ig_I-set.
DR   InterPro; IPR003599; Ig_sub.
DR   InterPro; IPR003598; Ig_sub2.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR011993; PH_dom-like.
DR   InterPro; IPR001849; PH_domain.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR001452; SH3_domain.
DR   InterPro; IPR018159; Spectrin/alpha-actinin.
DR   InterPro; IPR002017; Spectrin_repeat.
DR   InterPro; IPR028570; TRIO.
DR   PANTHER; PTHR22826:SF168; PTHR22826:SF168; 1.
DR   Pfam; PF00650; CRAL_TRIO; 1.
DR   Pfam; PF07679; I-set; 1.
DR   Pfam; PF00169; PH; 2.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00621; RhoGEF; 2.
DR   Pfam; PF00018; SH3_1; 1.
DR   Pfam; PF00435; Spectrin; 4.
DR   SMART; SM00409; IG; 1.
DR   SMART; SM00408; IGc2; 1.
DR   SMART; SM00233; PH; 2.
DR   SMART; SM00325; RhoGEF; 2.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00516; SEC14; 1.
DR   SMART; SM00326; SH3; 2.
DR   SMART; SM00150; SPEC; 6.
DR   SUPFAM; SSF48065; SSF48065; 2.
DR   SUPFAM; SSF48726; SSF48726; 1.
DR   SUPFAM; SSF50044; SSF50044; 2.
DR   SUPFAM; SSF50729; SSF50729; 2.
DR   SUPFAM; SSF52087; SSF52087; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50191; CRAL_TRIO; 1.
DR   PROSITE; PS50010; DH_2; 2.
DR   PROSITE; PS50835; IG_LIKE; 1.
DR   PROSITE; PS50003; PH_DOMAIN; 2.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50002; SH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Disease mutation; Disulfide bond;
KW   Guanine-nucleotide releasing factor; Immunoglobulin domain; Kinase;
KW   Mental retardation; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Serine/threonine-protein kinase;
KW   SH3 domain; Transferase.
FT   CHAIN         1   3097       Triple functional domain protein.
FT                                /FTId=PRO_0000080978.
FT   DOMAIN       65    210       CRAL-TRIO. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00056}.
FT   REPEAT      311    418       Spectrin 1.
FT   REPEAT      538    644       Spectrin 2.
FT   REPEAT      878    984       Spectrin 3.
FT   REPEAT     1109   1216       Spectrin 4.
FT   DOMAIN     1292   1467       DH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00062}.
FT   DOMAIN     1480   1591       PH 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN     1656   1712       SH3 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN     1969   2145       DH 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00062}.
FT   DOMAIN     2157   2271       PH 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00145}.
FT   DOMAIN     2551   2616       SH3 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00192}.
FT   DOMAIN     2685   2775       Ig-like C2-type.
FT   DOMAIN     2796   3052       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND    2802   2810       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   COMPBIAS    715    718       Poly-Gln.
FT   COMPBIAS   1845   1850       Poly-Ser.
FT   COMPBIAS   2292   2312       Poly-Gly.
FT   COMPBIAS   2545   2551       Poly-Ser.
FT   ACT_SITE   2915   2915       {ECO:0000250}.
FT   BINDING    2825   2825       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES    1627   1627       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q0KL02}.
FT   MOD_RES    2282   2282       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES    2455   2455       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2459   2459       Phosphoserine.
FT                                {ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES    2631   2631       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   DISULFID   2696   2759       {ECO:0000255|PROSITE-ProRule:PRU00114}.
FT   VAR_SEQ       1   2501       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_023306.
FT   VAR_SEQ       1     59       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037860.
FT   VAR_SEQ    2368   2368       G -> E (in isoform 2).
FT                                {ECO:0000303|PubMed:8643598}.
FT                                /FTId=VSP_004467.
FT   VAR_SEQ    2369   2544       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:8643598}.
FT                                /FTId=VSP_004468.
FT   VAR_SEQ    2502   2544       FPGDSDSLQRQTPRHAAPGKDTDRMSTCSSASEQSVQSTQS
FT                                NG -> MLPSQAQGLLWWVFPLFPASSLSYPPVSYRADGLA
FT                                RNTFLKAC (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_023307.
FT   VAR_SEQ    2545   2563       SESSSSSNISTMLVTHDYT -> VSASGGPRPPAPLPLSRQ
FT                                L (in isoform 5). {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_037861.
FT   VAR_SEQ    2564   3097       Missing (in isoform 5).
FT                                {ECO:0000303|Ref.7}.
FT                                /FTId=VSP_037862.
FT   VARIANT     291    291       S -> T (in dbSNP:rs55772118).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041899.
FT   VARIANT     348    348       D -> E (in dbSNP:rs16903367).
FT                                /FTId=VAR_059802.
FT   VARIANT     924    924       R -> S (in MRD44; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077093.
FT   VARIANT    1080   1080       N -> I (in MRD44; unknown pathological
FT                                significance; no effect on RAC1
FT                                activation).
FT                                {ECO:0000269|PubMed:27418539}.
FT                                /FTId=VAR_077094.
FT   VARIANT    1238   1238       Y -> H (in MRD44; unknown pathological
FT                                significance; dbSNP:rs756004023).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077095.
FT   VARIANT    1368   1368       D -> V. {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069371.
FT   VARIANT    1428   1428       R -> Q (in MRD44; strongly reduced RAC1
FT                                activation).
FT                                {ECO:0000269|PubMed:27418539}.
FT                                /FTId=VAR_077096.
FT   VARIANT    1461   1461       P -> T (in MRD44; strongly reduced RAC1
FT                                activation).
FT                                {ECO:0000269|PubMed:27418539}.
FT                                /FTId=VAR_077097.
FT   VARIANT    1613   1613       A -> T (in dbSNP:rs16903474).
FT                                /FTId=VAR_059803.
FT   VARIANT    1644   1644       T -> M (in dbSNP:rs55687522).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041900.
FT   VARIANT    1690   1690       H -> R (in dbSNP:rs56292586).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041901.
FT   VARIANT    1922   1922       A -> T (in MRD44; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077098.
FT   VARIANT    1939   1939       S -> N (in MRD44; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077099.
FT   VARIANT    1978   1978       V -> M (in a metastatic melanoma sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041902.
FT   VARIANT    2201   2201       L -> V (in MRD44; unknown pathological
FT                                significance; dbSNP:rs771342869).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077100.
FT   VARIANT    2242   2242       T -> M (in dbSNP:rs55916212).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_041903.
FT   VARIANT    2247   2247       E -> D (in MRD44; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077101.
FT   VARIANT    2563   2563       T -> M (in dbSNP:rs751663099).
FT                                {ECO:0000269|PubMed:23033978}.
FT                                /FTId=VAR_069372.
FT   VARIANT    2707   2707       R -> Q (in MRD44; unknown pathological
FT                                significance; dbSNP:rs768858988).
FT                                {ECO:0000269|PubMed:26721934}.
FT                                /FTId=VAR_077102.
FT   MUTAGEN    1299   1299       E->A: 50% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1303   1303       T->A: 40% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1389   1389       N->A: No change in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1426   1426       V->A: 90% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1427   1427       Q->A: 80% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1428   1428       R->A: 80% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1430   1430       T->A: 80% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1431   1431       K->A: Loss of nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1434   1434       L->A: 40% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1437   1437       K->A: No change in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   MUTAGEN    1438   1438       E->A: 30% decrease in nucleotide exchange
FT                                activity. {ECO:0000269|PubMed:9790533}.
FT   CONFLICT    550    553       QLEN -> HVRT (in Ref. 5; AAC34245 and 6;
FT                                AAC43042). {ECO:0000305}.
FT   CONFLICT    574    574       D -> E (in Ref. 5; AAC34245 and 6;
FT                                AAC43042). {ECO:0000305}.
FT   CONFLICT    787    788       QL -> HV (in Ref. 5; AAC34245 and 6;
FT                                AAC43042). {ECO:0000305}.
FT   HELIX      1291   1316       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1318   1324       {ECO:0000244|PDB:1NTY}.
FT   TURN       1331   1335       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1337   1341       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1344   1353       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1355   1361       {ECO:0000244|PDB:1NTY}.
FT   TURN       1362   1364       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1366   1369       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1370   1375       {ECO:0000244|PDB:1NTY}.
FT   TURN       1376   1380       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1381   1400       {ECO:0000244|PDB:1NTY}.
FT   TURN       1401   1403       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1404   1412       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1418   1422       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1424   1441       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1450   1470       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1473   1475       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1481   1483       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1486   1495       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1497   1501       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1504   1523       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1529   1538       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1539   1541       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1542   1545       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1549   1552       {ECO:0000244|PDB:2NZ8}.
FT   STRAND     1554   1562       {ECO:0000244|PDB:1NTY}.
FT   TURN       1565   1567       {ECO:0000244|PDB:1NTY}.
FT   STRAND     1569   1572       {ECO:0000244|PDB:1NTY}.
FT   HELIX      1576   1592       {ECO:0000244|PDB:1NTY}.
SQ   SEQUENCE   3097 AA;  346900 MW;  EA9236DF88B0EA24 CRC64;
     MSGSSGGAAA PAASSGPAAA ASAAGSGCGG GAGEGAEEAA KDLADIAAFF RSGFRKNDEM
     KAMDVLPILK EKVAYLSGGR DKRGGPILTF PARSNHDRIR QEDLRRLISY LACIPSEEVC
     KRGFTVIVDM RGSKWDSIKP LLKILQESFP CCIHVALIIK PDNFWQKQRT NFGSSKFEFE
     TNMVSLEGLT KVVDPSQLTP EFDGCLEYNH EEWIEIRVAF EDYISNATHM LSRLEELQDI
     LAKKELPQDL EGARNMIEEH SQLKKKVIKA PIEDLDLEGQ KLLQRIQSSE SFPKKNSGSG
     NADLQNLLPK VSTMLDRLHS TRQHLHQMWH VRKLKLDQCF QLRLFEQDAE KMFDWITHNK
     GLFLNSYTEI GTSHPHAMEL QTQHNHFAMN CMNVYVNINR IMSVANRLVE SGHYASQQIR
     QIASQLEQEW KAFAAALDER STLLDMSSIF HQKAEKYMSN VDSWCKACGE VDLPSELQDL
     EDAIHHHQGI YEHITLAYSE VSQDGKSLLD KLQRPLTPGS SDSLTASANY SKAVHHVLDV
     IHEVLHHQRQ LENIWQHRKV RLHQRLQLCV FQQDVQQVLD WIENHGEAFL SKHTGVGKSL
     HRARALQKRH EDFEEVAQNT YTNADKLLEA AEQLAQTGEC DPEEIYQAAH QLEDRIQDFV
     RRVEQRKILL DMSVSFHTHV KELWTWLEEL QKELLDDVYA ESVEAVQDLI KRFGQQQQTT
     LQVTVNVIKE GEDLIQQLRD SAISSNKTPH NSSINHIETV LQQLDEAQSQ MEELFQERKI
     KLELFLQLRI FERDAIDIIS DLESWNDELS QQMNDFDTED LTIAEQRLQH HADKALTMNN
     LTFDVIHQGQ DLLQYVNEVQ ASGVELLCDR DVDMATRVQD LLEFLHEKQQ ELDLAAEQHR
     KHLEQCVQLR HLQAEVKQVL GWIRNGESML NAGLITASSL QEAEQLQREH EQFQHAIEKT
     HQSALQVQQK AEAMLQANHY DMDMIRDCAE KVASHWQQLM LKMEDRLKLV NASVAFYKTS
     EQVCSVLESL EQEYKREEDW CGGADKLGPN SETDHVTPMI SKHLEQKEAF LKACTLARRN
     ADVFLKYLHR NSVNMPGMVT HIKAPEQQVK NILNELFQRE NRVLHYWTMR KRRLDQCQQY
     VVFERSAKQA LEWIHDNGEF YLSTHTSTGS SIQHTQELLK EHEEFQITAK QTKERVKLLI
     QLADGFCEKG HAHAAEIKKC VTAVDKRYRD FSLRMEKYRT SLEKALGISS DSNKSSKSLQ
     LDIIPASIPG SEVKLRDAAH ELNEEKRKSA RRKEFIMAEL IQTEKAYVRD LRECMDTYLW
     EMTSGVEEIP PGIVNKELII FGNMQEIYEF HNNIFLKELE KYEQLPEDVG HCFVTWADKF
     QMYVTYCKNK PDSTQLILEH AGSYFDEIQQ RHGLANSISS YLIKPVQRIT KYQLLLKELL
     TCCEEGKGEI KDGLEVMLSV PKRANDAMHL SMLEGFDENI ESQGELILQE SFQVWDPKTL
     IRKGRERHLF LFEMSLVFSK EVKDSSGRSK YLYKSKLFTS ELGVTEHVEG DPCKFALWVG
     RTPTSDNKIV LKASSIENKQ DWIKHIREVI QERTIHLKGA LKEPIHIPKT APATRQKGRR
     DGEDLDSQGD GSSQPDTISI ASRTSQNTLD SDKLSGGCEL TVVIHDFTAC NSNELTIRRG
     QTVEVLERPH DKPDWCLVRT TDRSPAAEGL VPCGSLCIAH SRSSMEMEGI FNHKDSLSVS
     SNDASPPASV ASLQPHMIGA QSSPGPKRPG NTLRKWLTSP VRRLSSGKAD GHVKKLAHKH
     KKSREVRKSA DAGSQKDSDD SAATPQDETV EERGRNEGLS SGTLSKSSSS GMQSCGEEEG
     EEGADAVPLP PPMAIQQHSL LQPDSQDDKA SSRLLVRPTS SETPSAAELV SAIEELVKSK
     MALEDRPSSL LVDQGDSSSP SFNPSDNSLL SSSSPIDEME ERKSSSLKRR HYVLQELVET
     ERDYVRDLGY VVEGYMALMK EDGVPDDMKG KDKIVFGNIH QIYDWHRDFF LGELEKCLED
     PEKLGSLFVK HERRLHMYIA YCQNKPKSEH IVSEYIDTFF EDLKQRLGHR LQLTDLLIKP
     VQRIMKYQLL LKDFLKYSKK ASLDTSELER AVEVMCIVPR RCNDMMNVGR LQGFDGKIVA
     QGKLLLQDTF LVTDQDAGLL PRCRERRIFL FEQIVIFSEP LDKKKGFSMP GFLFKNSIKV
     SCLCLEENVE NDPCKFALTS RTGDVVETFI LHSSSPSVRQ TWIHEINQIL ENQRNFLNAL
     TSPIEYQRNH SGGGGGGGSG GSGGGGGSGG GGAPSGGSGH SGGPSSCGGA PSTSRSRPSR
     IPQPVRHHPP VLVSSAASSQ AEADKMSGTS TPGPSLPPPG AAPEAGPSAP SRRPPGADAE
     GSEREAEPIP KMKVLESPRK GAANASGSSP DAPAKDARAS LGTLPLGKPR AGAASPLNSP
     LSSAVPSLGK EPFPPSSPLQ KGGSFWSSIP ASPASRPGSF TFPGDSDSLQ RQTPRHAAPG
     KDTDRMSTCS SASEQSVQST QSNGSESSSS SNISTMLVTH DYTAVKEDEI NVYQGEVVQI
     LASNQQNMFL VFRAATDQCP AAEGWIPGFV LGHTSAVIVE NPDGTLKKST SWHTALRLRK
     KSEKKDKDGK REGKLENGYR KSREGLSNKV SVKLLNPNYI YDVPPEFVIP LSEVTCETGE
     TVVLRCRVCG RPKASITWKG PEHNTLNNDG HYSISYSDLG EATLKIVGVT TEDDGIYTCI
     AVNDMGSASS SASLRVLGPG MDGIMVTWKD NFDSFYSEVA ELGRGRFSVV KKCDQKGTKR
     AVATKFVNKK LMKRDQVTHE LGILQSLQHP LLVGLLDTFE TPTSYILVLE MADQGRLLDC
     VVRWGSLTEG KIRAHLGEVL EAVRYLHNCR IAHLDLKPEN ILVDESLAKP TIKLADFGDA
     VQLNTTYYIH QLLGNPEFAA PEIILGNPVS LTSDTWSVGV LTYVLLSGVS PFLDDSVEET
     CLNICRLDFS FPDDYFKGVS QKAKEFVCFL LQEDPAKRPS AALALQEQWL QAGNGRSTGV
     LDTSRLTSFI ERRKHQNDVR PIRSIKNFLQ SRLLPRV
//
